설폰아미드 시장 예측(-2034년) : 종류, 제형, 투여 경로, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Sulphonamides Market is accounted for $141.53 million in 2026 and is expected to reach $245.00 million by 2034 growing at a CAGR of 7.1% during the forecast period. Sulphonamides are a class of synthetic antimicrobial drugs commonly used to treat bacterial infections. Acting as competitive inhibitors of folic acid synthesis in bacteria, they hinder essential metabolic processes, suppressing bacterial growth. Systemic sulphonamides are administered orally or parenterally for widespread infections, while topical formulations address localized issues. Their versatility extends to applications in both human and veterinary medicine.

According to NCBI, over 14 million cases of cellulitis are reported each year in the U.S., making it one of the most frequent bacterial skin infections. It is responsible for 650,000 hospital admissions per year and ambulatory care expenses of about USD 3.7 billion.

Market Dynamics:

Driver:

Increasing prevalence of infectious diseases

The mounting incidence of infectious diseases globally enhances the need for sulphonamides since these antimicrobial medicines successfully treat bacterial infections. Given the pressing need for efficient therapies against a variety of bacterial diseases, the pharmaceutical industry expects to see an increase in the use of these medications. This trend is particularly pronounced in regions with expanding populations and improving healthcare infrastructures, reinforcing sulphonamides' role in addressing the persistent challenge of infectious diseases on a broader scale.

Restraint:

Rising concerns about side effects

Concerns regarding possible side effects like rashes and allergic reactions are voiced by both patients and medical professionals, which hinders the drug's general uptake. Patients and healthcare professionals express apprehensions about potential adverse events, impacting the drug's overall adoption. The perceived risk of side effects can lead to a decline in patient compliance and reluctance among physicians to prescribe sulphonamides. This apprehension may divert preference towards alternative antibiotics or treatment options, hindering the market growth.

Opportunity:

Growing population and healthcare infrastructure

With a growing populace, the incidence of bacterial infections rises, fostering increased demand for effective treatments. Improved healthcare facilities, especially in developing regions, enhance access to sulphonamides, amplifying their usage. The strengthened healthcare infrastructure facilitates better diagnosis and treatment, promoting the adoption of sulphonamides in managing various infectious diseases. This dynamic synergy between population growth and enhanced healthcare capabilities positions sulphonamides as essential components in addressing the escalating healthcare needs of burgeoning societies.

Threat:

Limited spectrum of activity

In scenarios requiring broad-spectrum coverage, alternative antibiotics are the most favoured. Physicians, aiming for comprehensive treatments, may opt for antibiotics with a broader range of activity. The constrained scope of sulphonamides may result in their exclusion from treatment regimens, limiting their application and market share. This limitation hinders the versatility of sulphonamides, posing a challenge in situations where a more expansive antibacterial spectrum is deemed crucial for effective therapeutic interventions.

Covid-19 Impact

The covid-19 pandemic has influenced the sulphonamides market by disrupting supply chains, causing fluctuations in demand for antimicrobial agents. Healthcare priorities shifted towards managing the pandemic, impacting routine treatments. Disruptions in manufacturing and distribution channels, along with economic uncertainties, further affected the sulphonamides market. However, the essential nature of some sulphonamides in treating bacterial infections likely sustained demand, with the market adapting to ongoing challenges in the broader context of the global healthcare landscape.

The tablets segment is expected to be the largest during the forecast period

The tablets segment is estimated to have a lucrative growth. Sulphonamides tablets, a class of antimicrobial drugs, play a crucial role in treating bacterial infections. These tablets contain sulfa-based compounds that inhibit bacterial growth by interfering with folate synthesis. Commonly prescribed for urinary tract infections, respiratory tract infections, and other bacterial ailments, sulphonamide tablets offer a targeted therapeutic approach. Ongoing research aims to enhance formulations and overcome limitations, ensuring sulphonamide tablets continue to be effective and relevant in addressing a range of bacterial infections.

The antibacterial segment is expected to have the highest CAGR during the forecast period

The antibacterial segment is anticipated to witness the highest CAGR growth during the forecast period. Sulphonamides, as antibacterial agents, play a crucial role in combating bacterial infections. Widely utilized for their bacteriostatic properties, sulphonamides inhibit bacterial folate synthesis, impeding DNA and RNA production. This makes them effective against a range of bacterial pathogens. Their antibacterial application extends to respiratory, urinary, and skin infections. Sulphonamides continue to be pivotal in antibacterial therapeutics, contributing significantly to the global arsenal against bacterial diseases.

Region with largest share:

North America is projected to have the highest share over the forecast period, owing to its advanced healthcare infrastructure, robust research and development initiatives, and a high prevalence of infectious diseases. The region's well-established pharmaceutical sector fosters innovation in sulphonamide formulations. Further, North America remains a prominent market, with pharmaceutical advancements and a proactive approach toward infectious disease management fueling its continued prominence.

Region with highest CAGR:

The sulphonamides market in Asia Pacific is experiencing notable growth due to factors such as increasing healthcare infrastructure, rising prevalence of infectious diseases, and a burgeoning population. The region's expanding pharmaceutical industry, coupled with government initiatives to combat infections, propels market demand. With a focus on improving healthcare accessibility, countries in Asia Pacific are witnessing higher adoption of sulphonamides for treating bacterial infections. Additionally, ongoing research and development activities contribute to the market's dynamism, positioning Asia Pacific as a key player in the sulphonamides market.

Key players in the market

Some of the key players profiled in the Sulphonamides Market include Viatris Inc, Pfizer Inc, AA Pharma Inc, GlaxoSmithKline PLC, Azurity Pharmaceuticals, Teva Pharmaceutical Industries Limited, Valeo Pharma, Novartis Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Akorn Operating Company LLC, Sanofi S.A., Roche Holding AG, Merck & Co., Bayer AG, Johnson & Johnson, Abbott Laboratories, Bristol Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC and Boehringer Ingelheim International GmbH.

Key Developments:

In August 2022, Valeo Pharma Inc. and Novartis Pharmaceuticals Canada Inc., a subsidiary of Novartis AG, signed a supply and distribution agreement for SIMBRINZA in Canada. Brinzolamide is a carbonic anhydrase inhibitor and sulfonamide with a specific affinity for carbonic anhydrase II. This move ensured a broader reach of its products in the global market.

In July 2022, Azurity Pharmaceuticals Inc. received approval from the US FDA for ZONISADE (zonisamide oral suspension). Zonisamide is a sulfonamide antiepileptic drug.

Types Covered:

• Sulfamethoxazole
• Sulfadiazine
• Sulfacetamide
• Sulfasalazine
• Sulfadoxine
• Other Types

Formulations Covered:

• Tablets
• Liquid
• Powder
• Other Formulations

Route of Administrations Covered:

• Oral
• Parenteral
• Topical

Applications Covered:

• Antibacterial
• Antifungal
• Antimalarial
• Diuretic
• Antiviral
• Other Applications

End Users Covered:

• Pharmaceuticals
• Veterinary Medicine
• Agriculture
• Cosmetics
• Food & Beverage
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Sulphonamides Market, By Type

• 5.1 Introduction
• 5.2 Sulfamethoxazole
• 5.3 Sulfadiazine
• 5.4 Sulfacetamide
• 5.5 Sulfasalazine
• 5.6 Sulfadoxine
• 5.7 Other Types

6 Global Sulphonamides Market, By Formulation

• 6.1 Introduction
• 6.2 Tablets
• 6.3 Liquid
• 6.4 Powder
• 6.5 Other Formulations

7 Global Sulphonamides Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Topical

8 Global Sulphonamides Market, By Application

• 8.1 Introduction
• 8.2 Antibacterial
• 8.3 Antifungal
• 8.4 Antimalarial
• 8.5 Diuretic
• 8.6 Antiviral
• 8.7 Other Applications

9 Global Sulphonamides Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceuticals
• 9.3 Veterinary Medicine
• 9.4 Agriculture
• 9.5 Cosmetics
• 9.6 Food & Beverage
• 9.7 Other End Users

10 Global Sulphonamides Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Viatris Inc
• 12.2 Pfizer Inc
• 12.3 AA Pharma Inc
• 12.4 GlaxoSmithKline PLC
• 12.5 Azurity Pharmaceuticals
• 12.6 Teva Pharmaceutical Industries Limited
• 12.7 Valeo Pharma
• 12.8 Novartis Pharmaceuticals
• 12.9 Sun Pharmaceutical Industries Ltd
• 12.10 Akorn Operating Company LLC
• 12.11 Sanofi S.A.
• 12.12 Roche Holding AG
• 12.13 Merck & Co.
• 12.14 Bayer AG
• 12.15 Johnson & Johnson
• 12.16 Abbott Laboratories
• 12.17 Bristol Myers Squibb Company
• 12.18 Eli Lilly and Company
• 12.19 AstraZeneca PLC
• 12.20 Boehringer Ingelheim International GmbH